Furthermore, they also show that targeting cytoglobin and cardiolipins could enhance the therapeutic effectiveness of cisplatin in patients with head and neck cancer, a disease for which chemo-resistance remains a major therapeutic challenge. Here, CYGB is linked to head and neck cancer.